Search Bar & Filters
Found 1 Actively Recruiting clinical trials
Actively Recruiting
Researchers are evaluating the efficacy and safety of milsaperidone as an add-on treatment for patients with Major Depressive Disorder MDD who have not responded adequately to current antidepressant therapy. This phase 3, randomized, double-blind, placebo-controlled study aims to compare milsaperidone with a placebo to better understand its potential benefits and risks in this patient population. Participants will be randomly assigned to receive either oral milsaperidone or a matching placebo. The study uses a parallel design and involves multiple centers. The treatment period lasts 6 weeks, during which participants take the assigned oral medication as adjunctive therapy to their existing antidepressant regimen. During the study, participants will be closely monitored with regular assessments including the Montgomery-Asberg Depression Rating Scale MADRS to measure changes in depressive symptoms from baseline. Safety and tolerability will also be evaluated throughout the trial. The total duration of participation corresponds with the 6-week treatment and ongoing safety assessments, concluding by March 2028.